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Letters to the Editor
A mutation in exon 7 of the human cytochrome 
P>4501A1 gene as m arker for sensitivity to 
anti-cancer drugs?
Sir
One of the major problems in the anti-cancer drug treatment o f  
patients with malignant tumours is the development o f  anti-cancer 
drug resistance. Evidence is accumulating that anti-cancer drug 
resistance is a multifactorial phenomenon, and (a combination of) 
several different mechanisms may be responsible for the drug- 
resistant phenotype, such as an altered expression o f drug-metabo- 
lizing enzymes in tumour cells. Among other changes, compared 
with the parent MCF-7 WT (wild type) cells (Davies et al, 1996), 
low inducibility of cytochrome P-4501A l (CYP1A l ) and elevated 
expression o f glutathione S-transferase have been detected in 
multidrug-resistant MCF-7 Adr breast cancer cells (Ivy et al, 
1988). Many anti-cancer drugs require prior metabolic activation 
by CYP enzymes and, consequently, low  CYP activities could 
result in cells being insensitive to these agents (LeBlanc and 
Waxman, 1989; Chen et al, 1996). On the other hand, enhance­
ment o f detoxification o f  the anti-cancer drugs by glutathione S- 
transferases may also result in less efficient cytotoxic damage o f  
tumour cells (Hayes and Pulford, 1995).
A point mutation in exon 7 o f the human C Y P IA J  gene has been 
described which results in an isoleucine to valine substitution 
(Hayashi et al, 1991) and leads to an enhancement of* CYP1A! 
enzyme activity (Crofts et al, 1994); this can lead to a more efficient 
activation of anti-cancer drugs (LeBlanc and Waxman, 1989). This 
phenotype is present in the drug-sensitive MCF-7 WT breast cancer 
cells (Figure). The MCF-7 Adr multidrug-resistant cells, however,
; (Figure 1 ). This maypossess the non-mutated CYP1A1 
explain the observed C Y P IA 1 inducibility of the MCF-7 WT cells, 
which is absent in the MCF-7 Adr cell line (Ivy et al, 1988). As
of) C Y P IA 1above, deficient 
activity could lead to failure in activation of anti-cancer drugs and 
thus contribute to drug resistance.
In conclusion, it may be o f  importance to investigate a possible 
relationship between the mutation in exon 7 o f  the CYP1 A l gene 
(which is present in about 17% of Dutch Caucasians) and clinical 
sensitivity to particular (regimens of) anti-cancer drugs. The rapid 
polymerase chain reaction method for detection o f this poly­
morphism, as applied above, could then be of value in selecting 
patients for chemotherapy.
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Figure Detection of exon-7 CYP1A1 polymorphism by PCR. The presence 
of the CYP1A1 exon 7 mutation was investigated by PCR and restriction 
enzyme digestion with Ncol, essentially as described by Sheilds et al, 1993. 
The polymerase chain reaction was used to amplify 195-base pair fragments 
Wild type genes were identified by the presence of a Ncol restriction site 
yielding 32- and 163-base pair fragments, while the mutant gene missed this 
restriction site. Lane 1, DNA size markers; lane 2, drug resistant MCF-7 Adr 
PCR fragments after Ncol digestion (163 base pair fragments; 32 base pair 
fragments are not visible); lane 3, drug sensitive MCF-7 WT PCR fragments 
after Ncol digestion (both 195 and 163 base pair fragments, corresponding 
with heterozygote mutant genotype)
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